AI Article Synopsis
- - Epinephrine is the primary treatment for anaphylaxis, administered intramuscularly in the thigh at a dose of 0.01 mg/kg, with a max initial dose of 0.5 mg.
- - In Canada, epinephrine autoinjectors come in three doses: 0.15 mg, 0.30 mg, and 0.50 mg, but there's a lack of studies comparing the 0.3 mg and 0.5 mg doses for effectiveness.
- - The CSACI advises that for individuals weighing 45 kg or more, doctors should consider prescribing the 0.50 mg EAI after discussing it with the patient, as larger individuals may receive inadequate dosing with
Article Abstract
Epinephrine is the first line treatment for anaphylaxis, an acute potentially life-threatening allergic reaction. It is typically administered intramuscularly in the anterolateral thigh at a dose of 0.01 mg/kg of 1:1000 (1 mg/ml) solution to a maximum initial dose of 0.5 mg. Currently in Canada, epinephrine autoinjectors (EAI) are available in three doses, 0.15 mg, 0.30 mg, and 0.50 mg. There are currently no published studies comparing 0.3 mg and 0.5 mg EAIs in the paediatric or adult populations to compare clinical effectiveness. However, as weight increases above 30 kg, the percentage of the recommended 0.01 mg/kg epinephrine dose from an existing 0.3 mg EAI decreases resulting in potential underdosing. As such, The Canadian Society of Allergy and Immunology (CSACI) recommends that for those who weigh ≥ 45 kg, physicians could consider prescribing the 0.50 mg EAI based on shared decision making with patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670273 | PMC |
| http://dx.doi.org/10.1186/s13223-021-00634-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!